Edition:
United States

Nymox Pharmaceutical Corp (NYMX.OQ)

NYMX.OQ on NASDAQ Stock Exchange Capital Market

3.57USD
4:00pm EDT
Change (% chg)

$0.37 (+11.56%)
Prev Close
$3.20
Open
$3.16
Day's High
$4.10
Day's Low
$3.16
Volume
336,206
Avg. Vol
31,259
52-wk High
$5.77
52-wk Low
$1.62

Latest Key Developments (Source: Significant Developments)

Nymox expects submission of initial filing seeking approval for Fexapotide Triflutate in next few weeks
10:45am EDT 

Nymox Pharmaceutical Corp : Nymox provides update on Fexapotide development ."Now expects to submit its initial filing seeking approval for Fexapotide Triflutate in next few weeks".  Full Article

Nymox Pharmaceutical reports results of prostate cancer study
Wednesday, 22 Jun 2016 09:30am EDT 

Nymox Pharmaceutical Corp : Nymox reports long-term prostate cancer results in 7 year prospective study of 995 u.s. Middle-Aged and elderly men without cancer . Men who received fexapotide showed a major reduction in incidence of prostate cancer, compared to placebo . Men who received fexapotide showed major reduction in incidence of prostate cancer versus placebo and versus known and expected normal incidence of disease .New data analysis has now shown statistically significant and very low incidence of 1.3% for prostate cancer in comparable fexapotide treated bph population.  Full Article

Nymox Pharmaceutical Corp announces prostate cancer clinical trial results from completed 18 month endpoint study
Tuesday, 9 Feb 2016 10:00am EST 

Nymox Pharmaceutical Corp:Announces prostate cancer clinical trial results from completed 18 month endpoint study.Says the study successfully met its pre-determined endpoints.Says cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.  Full Article

Nymox Pharmaceutical Corp announces additional $2.1 mln equity financing
Thursday, 4 Feb 2016 11:15am EST 

Nymox Pharmaceutical Corp:Announces additional $2.1 million equity financing.Says has now closed private placements totalling $3.4 million since November 5.Says the investment was at $2.00 per share with no warrants.  Full Article

Nymox Pharmaceutical Corp reports results of prospective cross-over study of fexapotide treatment for prostate cancer
Thursday, 29 Oct 2015 10:31am EDT 

Nymox Pharmaceutical Corp:Reports results of prospective cross-over study of fexapotide treatment for prostate cancer.Study shows randomized control subjects who subsequently switched to fexapotide had long-term outcomes significantly superior.Primary endpoint of the study also reached statistical significance (p <.03) in the cross-over study.Expects to report results from its long-term nx03-0040 low grade localized prostate cancer study in the fourth quarter.  Full Article

Nymox Appoints Cutler & Co. as Auditor
Thursday, 16 Jul 2015 06:03pm EDT 

Nymox Pharmaceutical Corp:Approved the engagement of Cutler & Co., LLC to serve as the Company's new independent registered public accounting firm to replace KPMG LLP.  Full Article

Nymox Pharmaceutical Corporation appoints Erik Danielsen as CFO
Monday, 13 Jul 2015 01:15pm EDT 

Nymox Pharmaceutical Corporation:Appoints Erik Danielsen as CFO.Erik Danielsen replaces Andre Monette.  Full Article

Nymox Pharmaceutical Corp announces prostate cancer clinical trial results
Monday, 20 Apr 2015 10:00am EDT 

Nymox Pharmaceutical Corp:Says results demonstrate statistically significant (p=.0067) better outcomes at up to 2.8 years for NX-1207 treated patients compared to controls.Says study found after up to 2.8 years for NX-1207 single-injection treated patients there was 68.2 pct reduction compared to controls in proportion of patients who had upgraded blinded biopsy.Study also found all instances of surgery or radiation, including elective cases without upgrades, were decreased by 62.7 pct.To date, NX-1207 has had safety profile.NX-1207 has shown safety in 9 clinical trials (BPH and prostate cancer) including repeat injection studies.Drug does not lead to immune responses such as antibody formation which can cause drug toxicity and/or limit usage to single treatments due to drug neutralizing effects.  Full Article

More From Around the Web

BRIEF-Nymox reports additional positive data from fexapotide BPH phase 3 trial

* Nymox reports additional positive results from completed fexapotide BPH phase 3 studies showing significant early response and first-line efficacy